SC2073 / Dong-A, Korea Kolmar - LARVOL DELTA

Dong-A ST announces non-clinical results of EGFR target protein decomposition agent 'SC2073' at US AACR [Google translation] (BioTimes) - "At this conference, Dong-A ST will present the results of a nonclinical study on its EGFR target protein decomposition agent, 'SC2073 (IN-207039),' which is currently under development for patients with non-small cell lung cancer (NSCLC) with EGFR resistance mutations. It will introduce the latest research results for overcoming resistance due to EGFR mutations and the new potential of 'SC2073 (IN-207039)' for the treatment of non-small cell lung cancer."

Preclinical • Non Small Cell Lung Cancer

Discovery of SC2073, a potent and mutant selective EGFR degrader that overcomes 3rd generation EGFR inhibitors resistance in NSCLC (AACR 2025) - "SC2073 effectively inhibited the proliferation of Ba/F3 cell expressing EGFR mutants while sparing WT EGFR cells and it demonstrated robust anti-tumor activity in EGFR mutation-driven in vivo tumor models. Our data suggests that SC2073 could be a promising treatment option for NSCLC patients harboring various EGFR mutations, including L858R, T790M, and C797S, which are associated with acquired resistance to EGFR inhibitors."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CRBN • GSPT1 • SALL4